[1] Lee-Sundlov M M,Stowell S R,Hoffmeister K M. Multifaceted role of glycosylation in transfusion medicine, platelets,and red blood cells[J]. J Thromb Haemost,2020, 18(7):1535-1547. [2] Ward S E,O'Sullivan J M,O'Donnell J S. The relationship between ABO blood group,von Willebrand factor,and primary hemostasis[J]. Blood,2020,136(25):2864-2874. [3] Cain L,Aggarwal A,Geneen L J,et al.ABO matching for platelet transfusions for prevention or treatment of bleeding: A systematic review with meta-analysis[J]. Transfus Med Rev,2026,40(1):150928. [4] Jajosky R P,Wu S C,Zheng L,et al.ABO blood group antigens and differential glycan expression: Perspective on the evolution of common human enzyme deficiencies[J]. iScience,2023,26(1):105798. [5] Mollicone R,Caillard T,Le Pendu J,et al.Expression of ABH and X (Lex) antigens on platelets and lymphocytes[J]. Blood,1988,71(4):1113-1119. [6] Holgersson J,Breimer M E,Jacobsson A,et al.Glycolipid- and glycoprotein-based blood group A antigen expression in human thrombocytes. A1/A2 difference[J]. Glycoconj J, 1990,7(6):601-608. [7] Santoso S,Kiefel V,Mueller-Eckhardt C.Blood group a and B determinants are expressed on platelet glycoproteins Ⅱa,Ⅲa,and ⅰb[J]. Thromb Haemost,1991,65(2):196-201. [8] Hou M,Stockelberg D,Rydberg L,et al.Blood group A antigen expression in platelets is prominently associated with glycoprotein Ⅰb and Ⅱb. Evidence for an A1/A2 difference[J]. Transfus Med,1996,6(1):51-59. [9] Kelton J G,Smith J W,Horsewood P,et al.ABH antigens on human platelets: expression on the glycosyl phosphatidylinositol-anchored protein CD109[J]. J Lab Clin Med,1998,132(2):142-148. [10] Hollenhorst M A,Tiemeyer K H,Mahoney K E, et al.Comprehensive analysis of platelet glycoprotein Ibα ectodomain glycosylation[J]. J Thromb Haemost,2023, 21(4):995-1009. [11] Skogen B,Rossebø Hansen B,Husebekk A,et al.Minimal expression of blood group A antigen on thrombocytes from A2 individuals[J]. Transfusion,1988,28(5):456-459. [12] Cooling L L,Kelly K,Barton J,et al.Determinants of ABH expression on human blood platelets[J]. Blood, 2005,105(8):3356-3364. [13] Dunstan R A,Simpson M B,Knowles R W,et al.The origin of ABH antigens on human platelets[J]. Blood, 1985,65(3):615-619. [14] Ogasawara K,Ueki J,Takenaka M,et al.Study on the expression of ABH antigens on platelets[J]. Blood,1993,82(3):993-999. [15] Curtis B R,Edwards J T,Hessner M J,et al.Blood group A and B antigens are strongly expressed on platelets of some individuals[J]. Blood,2000,96(4):1574-1581. [16] O'Donghaile D,Jenkins P V,McGrath R T,et al. Expresser phenotype determines ABO(H) blood group antigen loading on platelets and von Willebrand factor[J]. Sci Rep,2020,10(1):18366. [17] Hindle M S,Cheah L T,Yates D M,et al.Preanalytical conditions for multiparameter platelet flow cytometry[J]. Res Pract Thromb Haemost,2023,7(7):102205. [18] Canis K,McKinnon T A,Nowak A,et al. Mapping the N-glycome of human von willebrand factor[J]. Biochem J,2012,447(2):217-228. [19] Ward S,O'Sullivan J M,O'Donnell J S. The biological significance of von willebrand factor O-linked glycosylation[J]. Semin Thromb Hemost,2021,47(7):855-861. [20] Swystun L L,Lillicrap D.Genetic regulation of plasma von Willebrand factor levels in health and disease[J]. J Thromb Haemost,2018,16(12):2375-2390. [21] Ward S,O'Sullivan J M,O'Donnell J S. Von Willebrand factor sialylation-a critical regulator of biological function[J]. J Thromb Haemost,2019,17(7):1018-1029. [22] Murray G P,Post S R,Post G R.ABO blood group is a determinant of von Willebrand factor protein levels in human pulmonary endothelial cells[J]. J Clin Pathol,2020, 73(6):347-349. [23] Dunne E,Qi Q M,Shaqfeh E S,et al.Blood group alters platelet binding kinetics to von Willebrand factor and consequently platelet function[J]. Blood,2019,133(12): 1371-1377. [24] Nowak A A,Canis K,Riddell A,et al.O-linked glycosylation of von Willebrand factor modulates the interaction with platelet receptor glycoprotein Ib under static and shear stress conditions[J]. Blood,2012,120(1): 214-222. [25] Bonazza K,Iacob R E,Hudson N E,et al.Von Willebrand factor A1 domain stability and affinity for GPⅠbα are differentially regulated by its O-glycosylated N- and C-linker[J]. eLife,2022,11:e75760. [26] Cao Y W,Zhang X F,Im W.Dynamics of a von willebrand factor A1 autoinhibitory module with O-linked glycans and its roles in regulation of GPⅠbα binding[J]. J Phys Chem B,2025,129(15):3796-3806. [27] Refaai M A,Henrichs K F,Spinelli S L,et al.Platelet activation following exposure to anti-ABO antibodies-an in vitro study[J]. US Oncol Hematol,2011,7(1):72-74. [28] Refaai M A,Carter J,Henrichs K F,et al.Alterations of platelet function and clot formation kinetics after in vitro exposure to anti-A and-B[J]. Transfusion,2013,53(2): 382-393. [29] Dunbar N M.Does ABO and RhD matching matter for platelet transfusion?[J]. Hematology Am Soc Hematol Educ Program,2020,2020(1):512-517. [30] Heal J M,Rowe J M,McMican A,et al. The role of ABO matching in platelet transfusion[J]. European J Haematology,1993,50(2):110-117. [31] Pandey P,Kumari S,Mandal S,et al.A prospective observational study to compare transfusion outcomes in ABO identical versus ABO non-identical single donor platelet concentrates: An experience from a tertiary healthcare center in India[J]. Transfus Clin Biol,2022, 29(3):213-218. [32] Das N,Prakash S,Sahu A,et al.Impact of dose and storage duration of platelet concentrates on platelet recovery between ABO identical and ABO non-identical random donor platelet transfusions in hemato-oncology patients[J]. Hematol Transfus Cell Ther,2024,46(3):228-236. [33] Bougie D W,Reese S E,Birch R J,et al.Associations between ABO non-identical platelet transfusions and patient outcomes-a multicenter retrospective analysis[J]. Transfusion,2023,63(5):960-972. [34] Magid-Bernstein J,Beaman C B,Carvalho-Poyraz F, et al.Impacts of ABO-incompatible platelet transfusions on platelet recovery and outcomes after intracerebral hemorrhage[J]. Blood,2021,137(19):2699-2703. [35] Dunn L K,Venner E,Nguyen M,et al.ABO-identical versus incompatible platelet transfusion in patients with intracranial hemorrhage[J]. PLoS One,2024,19(11): e0312602. [36] Yildiz A,Yaman S,Çiftçiler R,et al.Safety of ABO-incompatible platelet transfusions: a multicenter retrospective cohort study[J]. J Patient Saf,2026,22(4):296-299. [37] Blumberg N,Heal J M,Hicks G L Jr,et al. Association of ABO-mismatched platelet transfusions with morbidity and mortality in cardiac surgery[J]. Transfusion,2001, 41(6):790-793. [38] Zulkeflee R H,Hassan M N,Hassan R,et al.Acute hemolytic transfusion reaction following ABO-mismatched platelet transfusion: Two case reports[J]. Transfus Apher Sci,2023,62(3):103658. [39] Bienz M,Gupta A,Goldstein J,et al.Severe acute haemolytic transfusion reaction secondary to a plasma incompatible group B platelet transfusion[J]. Transfus Med,2023,33(2):188-193. [40] Augustine M,Murugesan M,Gopakumar K G,et al.Case report and strategies to mitigate passive hemolysis with platelet transfusions in children[J]. Asian J Transfus Sci, 2021,15(2):229-232. [41] Gehrie E A,Savani B N,Booth G S.Risk factors for hemolytic transfusion reactions resulting from ABO and minor red cell antigen incompatibility: From mislabeled samples to stem cell transplant and sickle cell disease[J]. Blood Rev,2021,45:100719. [42] Malvik N,Leon J,Schlueter A J,et al.ABO-incompatible platelets are associated with increased transfusion reaction rates[J]. Transfusion,2020,60(2):285-293. [43] Hogan K O,Mudunkotuwa G,Phadnis M,et al.ABO incompatibility and component irradiation are independently associated with platelet transfusion reaction rate[J]. Transfusion,2025,65(3):496-504. [44] Aguilar G,Ortiz N,Gonzales D,et al.High titers of anti-A1 and anti-B antibodies among Peruvian group O platelet donors[J]. Transfus Apher Sci,2022,61(3):103341. [45] Hua Q Y,Lyon B W,Duke J,et al.Isohemagglutinin titration in pooled and apheresis platelets[J]. Transfusion, 2024,64(7):1279-1286. [46] Murugesan M,Augustine M,Velayudhan S C,et al.Hemolysin test as a tool to screen high-titer Group O platelet apheresis donors: A prospective study[J]. Asian J Transfus Sci,2023,17(2):189-194. [47] Bastos E P,Castilho L,Bub C B,et al.Comparison of ABO antibody titration,IgG subclasses and qualitative haemolysin test to reduce the risk of passive haemolysis associated with platelet transfusion[J]. Transfus Med, 2020,30(4):317-323. [48] Weisberg S P,Shaz B H,Tumer G,et al.PAS-C platelets contain less plasma protein,lower anti-A and anti-B titers, and decreased HLA antibody specificities compared to plasma platelets[J]. Transfusion,2018,58(4):891-895. [49] Pagano M B,Katchatag B L,Khoobyari S,et al.Evaluating safety and cost-effectiveness of platelets stored in additive solution (PAS-F) as a hemolysis risk mitigation strategy[J]. Transfusion,2019,59(4):1246-1251. [50] Adzahar S,Hassan M N,Zulkafli Z,et al.Platelet additive solutions as an alternative storage medium of apheresis platelets to reduce ABO antibody titer for ABO-incompatibility platelet transfusion[J]. Cureus,2023,15(8): e44012. [51] Jung Y,Luo O,Sen N N,et al.The safety of ABO minor incompatible platelets transfusions using a rapid infuser[J]. Transfusion,2024,64(3):449-453. [52] Cohn C S.Platelet transfusion refractoriness: how do I diagnose and manage?[J]. Hematology Am Soc Hematol Educ Program,2020,2020(1):527-532. [53] 中华医学会血液学分会. 血小板无效输注诊断和治疗中国专家共识(2022年版)[J]. 中华血液学杂志,2022, 43(11):897-902. [54] Matsui R,Hagino T,Tsuno N H,et al.Does time of CCI measurement affect the evaluation of platelet transfusion effectiveness?[J]. Transfus Apher Sci,2021,60(3):103123. [55] Belizaire R,Makar R S.Non-alloimmune mechanisms of thrombocytopenia and refractoriness to platelet transfusion[J]. Transfus Med Rev,2020,34(4):242-249. [56] Blandin L,Dougé A,Fayard A,et al.Platelet transfusion refractoriness and anti-HLA immunization[J]. Transfusion, 2021,61(6):1700-1704. [57] Arabi S,Almahayni A O,Alomair A A,et al.Prevalence, risk factors,and outcomes of platelet transfusion refractoriness in critically ill patients: a retrospective cohort study[J]. Crit Care Res Pract,2021,2021: 5589768. [58] Han M H,Badami K G.ABO non-identical platelet transfusions,immune platelet refractoriness and platelet support[J]. Br J Haematol,2024,204(5):2097-2102. [59] Gammon R,Mo A.The importance of ABO in platelet refractoriness,an often overlooked option[J]. Br J Haematol,2024,204(5):1602-1604. [60] Garraud O,Hamzeh-Cognasse H,Chalayer E,et al.Platelet transfusion in adults: An update[J]. Transfus Clin Biologique,2023,30(1):147-165. [61] McCullagh J,Cardigan R,Brunskill S J,et al. Assessing the risks of haemolysis as an adverse reaction following the transfusion of ABO incompatible plasma-containing components - A scoping review[J]. Blood Rev,2022,56: 100989. [62] Shen C Y,Bengtsson J,Jöud M,et al.When is ABO-incompatible plasma safe to transfuse? Defining an empirical estimation of anti-A/anti-B in ABO incompatible plasma-containing blood products[J]. Blood Transfus, 2025,23(5):393-408. [63] Andreu G,Boudjedir K,Meyer N,et al.Platelet additive solutions and pathogen reduction impact on transfusion safety,patient management and platelet supply[J]. Transfus Med Rev,2025,39(1):150875. [64] Yıldız A,Doğan M,Yalvaç M,et al.Platelet inventory and using out-of-group platelet suspension: a cost-effective strategy for a blood transfusion service[J]. Hematol Oncol Stem Cell Ther,2023,16(4):337-341. |